View Filing Data

Stock-Based Compensation, Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Nov. 06, 2019	Oct. 25, 2019	Dec. 31, 2018
Class of Warrant or Right [Abstract]
Exercise price of warrants (in dollars per share)		$ 0.9942	$ 1.41
Warrants [Member]
Class of Warrant or Right [Abstract]
Warrants outstanding (in shares)	6,948,466			599,293
Warrants [Member] \| Minimum [Member]
Class of Warrant or Right [Abstract]
Exercise price of warrants (in dollars per share)	$ 0.99
Warrants exercisable period	9 months
Warrants [Member] \| Maximum [Member]
Class of Warrant or Right [Abstract]
Exercise price of warrants (in dollars per share)	$ 43,848
Warrants exercisable period	5 years 6 months

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 1,279	$ 5,480
Accounts receivable	799	786
Inventories	1,797	1,658
Other current assets	161	203
Total current assets	4,036	8,127
Property, plant and equipment, net	991	536
Operating lease right-of-use asset, net	442	0
Other assets	133	113
TOTAL ASSETS	5,602	8,776
Current liabilities
Accounts payable	1,488	1,133
Accrued compensation	1,592	1,498
Current portion of operating lease liability	186	0
Other current liabilities	85	209
Total current liabilities	3,351	2,840
Operating lease liability	261	0
Total liabilities	3,612	2,840
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of December 31, 2019 and December 31, 2018, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 4,674,068 and 513,445, respectively	0	0
Additional paid-in capital	218,278	204,101
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,214	1,223
Accumulated deficit	(217,502)	(199,388)
Total stockholders' equity	1,990	5,936
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	5,602	8,776
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	$ 0	$ 0

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 0	$ 197,367	$ 1,227	$ (182,356)	$ 16,238
Balance (in shares) at Dec. 31, 2017	271,357
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(17,032)	(17,032)
Foreign currency translation adjustment	0	0	(4)	0	(4)
Stock-based compensation, net	$ 0	2,087	0	0	2,087
Stock-based compensation, net (in shares)	12
Issuance of unregistered shares	$ 0	0	0	0	0
Issuance of unregistered shares (in shares)	7,116
Issuance of common stock, net	$ 0	4,647	0	0	4,647
Issuance of common stock, net (in shares)	181,941
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	53,019
Balance at Dec. 31, 2018	$ 0	204,101	1,223	(199,388)	5,936
Balance (in shares) at Dec. 31, 2018	513,445
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(18,114)	(18,114)
Foreign currency translation adjustment	0	0	(9)	0	(9)
Stock-based compensation, net	$ 0	1,512	0	0	1,512
Stock-based compensation, net (in shares)	3
Issuance of common stock, net	$ 0	12,665	0	0	12,665
Issuance of common stock, net (in shares)	2,250,084
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	1,910,536
Balance at Dec. 31, 2019	$ 0	$ 218,278	$ 1,214	$ (217,502)	$ 1,990
Balance (in shares) at Dec. 31, 2019	4,674,068

Revenue Recognition	12 Months Ended
Revenue Recognition	Dec. 31, 2019
Revenue Recognition [Abstract]
Revenue Recognition	Note 2—Revenue Recognition Net Sales The Company sells its products in the United States primarily through a direct sales force. Customers who purchase the Company’s products include hospitals and clinics throughout the United States. In countries outside the United States, the Company sells its products through a limited number of specialty healthcare distributors in the United Kingdom, Italy, Spain, Germany, Austria, Switzerland, Southeast Asia, Brazil, India and Greece. These distributors resell the Company’s products to hospitals and clinics in their respective geographies. Revenue from product sales are recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company’s standard shipping terms are FOB shipping point, unless the customer requests that control and title to the inventory transfer upon delivery. Revenue is measured as the amount of consideration the Company expects to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers which are recognized over time. This revenue represents less than 1% of net sales for the years ended December 31, 2019 and 2018. The unfulfilled performance obligations related to these extended service plans is included in deferred revenue, which is included in other current liabilities on the consolidated balance sheets. The majority of the deferred revenue is expected to be recognized within one year. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold. Product Returns: The Company offers customers a limited right of return for its product in case of non-conformity or performance issues. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own historical sales and returns information. The Company has not received any returns to date and believes that future returns of its products will be minimal. Therefore, revenue recognized is not currently impacted by variable consideration related to product returns.

Operating Leases

12 Months Ended

Dec. 31, 2019

Operating Leases [Abstract]

Operating Leases

Note 9—Operating Leases

The Company leases office and manufacturing space under a non-cancelable operating lease that expires in March 2022. In August 2018, the Company entered into a third amendment to the lease, extending the term of the lease from March 31, 2019 to March 31, 2022. Beginning on April 1, 2019, the annual base rent is $9.00 per square foot, subject to annual increases of $0.25 per square foot.

The cost components of the Company’s operating lease were as follows for the year ended December 31:

(in thousands)
Operating lease cost	$	213
Variable lease cost		102
Total	$	315

Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased office and manufacturing space.

Maturities of our lease liability for the Company’s operating lease are as follows as of December 31, 2019:

(in thousands)
2020	$	213
2021		219
2022		55
Total lease payments		487
Less: Interest		(40	)
Present value of lease liability	$	447

As of December 31, 2019, the remaining lease term was 2.25 years and discount rate was 7.5%. For the year ended December 31, 2019, the operating cash outflows from the Company’s operating lease for office and manufacturing space were $206,000.

Rent expense related to operating leases for office and manufacturing space and office equipment was approximately $293,000 for the year ended December 31, 2018. Future minimum lease payments, under non-cancelable operating leases as of December 31, 2018, were approximately $217,000, $220,000, $219,000, $55,000, and $0 for each of the years ended December 31, 2019, through 2023, respectively.

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value of Financial Instruments [Abstract]

Fair Value of Level 3 Warrants

The following is a rollforward of the fair value of Level 3 items:

(in thousands)
Balance December 31, 2018	$	126
Change in fair value		(126	)
Balance as of December 31, 2019	$	-

Segment and Geographic Information (Details)	12 Months Ended
Segment and Geographic Information (Details)	Dec. 31, 2019 Segment
Segment and Geographic Information [Abstract]
Number of reportable segments	1

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Stock-Based Compensation [Abstract]

Summary of Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense which was recognized in the consolidated statements of operations for the years ended December 31,

(Dollars in thousands)	2019		2018
Selling, general and administrative	$	1,387	$	1,958
Research and development		125		129
Total	$	1,512	$	2,087

Summary of Plan Stock Option Activity

The following is a summary of the Plans’ stock option activity during the years ended December 31:

	2019					2018
	Options Outstanding			Weighted Average Exercise Price		Options Outstanding			Weighted Average Exercise Price
Beginning Balance		140,546		$	61.25		2,562		$	1,049.93
Granted		281,834			2.38		163,997			45.76
Exercised		—			—		—			—
Forfeited/expired		(16,650	)		31.77		(26,013	)		61.01
Outstanding at December 31		405,730		$	21.56		140,546		$	61.25
Vested at December 31		72,377		$	74.21		16,206		$	169.07

Weighted Average Assumptions used in Black-Scholes Option Pricing Model

The following table provides the weighted average assumptions used in the Black-Scholes option pricing model for the years ended December 31:

	2019			2018
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.85	%		2.49	%
Expected volatility		121.67	%		120.54	%
Expected life (in years)		6.22			6.23

Summary of Restricted Stock Award Activity

The following table summarizes restricted stock award activity during 2019 and 2018:

	2019					2018
	RSUs			Weighted Average Grant Price		RSUs			Weighted Average Grant Price
Nonvested, beginning balance		3		$	7,297.22		15		$	7,297.22
Granted		—			—		—			—
Vested		(3	)	$	7,297.22		(12	)		7,297.22
Forfeited		—			—		—			—
Nonvested at December 31		—			—		3		$	7,297.22

Segment and Geographic Information	12 Months Ended
Segment and Geographic Information	Dec. 31, 2019
Segment and Geographic Information [Abstract]
Segment and Geographic Information	Note 12—Segment and Geographic Information The Company has one reportable segment, cardiac and coronary disease products. At December 31, 2019 and 2018, long-lived assets were located primarily in the United States.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2019

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

Note 7—Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, warrants, and contingent consideration.

Pursuant to the requirements of ASC Topic 820 “Fair Value Measurement,” the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

•	Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges.

•

Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

•	Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

The fair value of the Company's contingent consideration, as described in Note 1, was initially measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value, and it was considered a Level 3 instrument. The discount rate used was determined at the time of measurement in accordance with accepted valuation methods. The Company measured the liability on a recurring basis using Level 3 inputs including probabilities of payment and projected payment dates. As of December 31, 2019, this contingency had expired, therefore its fair value was recorded at $0.

The following is a rollforward of the fair value of Level 3 items:

(in thousands)
Balance December 31, 2018	$	126
Change in fair value		(126	)
Balance as of December 31, 2019	$	-

The fair value of the market-based warrants described in Note 5 was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. These warrants are classified as permanent equity and as a result, were measured at the grant date and are not required to be remeasured to fair value at each reporting period end.

All cash equivalents are considered Level 1 measurements for all periods presented. The Company does not have any financial instruments classified as Level 2 or any other classified as Level 3 and there were no movements between these categories during the periods ended December 31, 2019 and December 31, 2018. The Company believes that the carrying amounts of all remaining financial instruments approximate their fair value due to their relatively short maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Nature of Business and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Nature of Business and Significant Accounting Policies [Abstract]

Inventories

Inventories consisted of the following as of December 31:


	2019		2018
Finished Goods	$	750	$	517
Work in Process		79		34
Raw Materials		968		1,107
Total	$	1,797	$	1,658

Estimated Useful Lives

Depreciation expense has been calculated using the following estimated useful lives:

Production Equipment		3-7 years
Office Furniture and Fixtures		3-5 years
Computer Software and Equipment		3-4 years
Loaners and Demo Equipment		3-7 years
Leasehold Improvements		3-5 years

Potential Shares of Common Stock not Included in Diluted Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each year presented:


	December 31,
	2019		2018
Stock options		405,730		140,546
Restricted stock units (RSU)		—		3
Warrants to purchase common stock		6,948,466		599,293
Series F convertible preferred stock		538,210		18,190
Total		7,892,406		758,032

Reconciles Reported Net Loss with Reported Net Loss Per Share

The following table reconciles reported net loss with reported net loss per share for the years ended December 31:


(in thousands, except per share amounts)	2019			2018
Net loss	$	(18,114	)	$	(17,032	)
Deemed dividend to preferred shareholders (see Note 6)		(4,509	)		—
Net loss after deemed dividend		(22,623	)		(17,032	)
Weighted average shares outstanding		2,433			404
Basic and diluted loss per share	$	(9.30	)	$	(42.14	)

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Taxes [Abstract]

Income Taxes

Note 8—Income Taxes

Domestic and foreign loss before income taxes, consists of the following for the years ended December 31:

(in thousands)	2019			2018
Domestic	$	(18,114	)	$	(17,027	)
Foreign		8			1
Loss before income taxes	$	(18,106	)	$	(17,026	)

The components of income tax expense consist of the following for the years ended December 31:

(in thousands)	2019			2018
Current:
United States and state	$	—		$	—
Foreign, net		(8	)		(6	)
Deferred:
United States and state		—			—
Foreign		—			—
Total income tax expense	$	(8	)	$	(6	)

Actual income tax expense differs from statutory federal income tax expense as follows for the years ended December 31:

(in thousands)	2019			2018
Statutory federal income tax benefit	$	3,802		$	3,578
State tax benefit, net of federal taxes		46			45
Foreign tax		1			(2	)
Foreign deferred exchange rate adjustments		(59	)		(1,112	)
Nondeductible/nontaxable items		(272	)		(259	)
Other		(113	)		(72	)
Valuation allowance increase		(3,413	)		(2,184	)
Total income tax expense	$	(8	)	$	(6	)

Deferred taxes consist of the following as of December 31:

(in thousands)	2019			2018
Deferred tax assets:
Noncurrent:
Accrued leave	$	51		$	50
Other accrued expenses		—			—
Stock based compensation		449			483
Net operating loss carryforward		44,572			41,032
Other		69			125
Intangibles		809			847
R&D credit carryforward		531			531
Total deferred tax assets		46,481			43,068
Less: valuation allowance		(46,481	)		(43,068	)
Total	$	—		$	—

As of December 31, 2019, the Company had federal net operating loss (“NOLs”) carryforwards of approximately $152.1 million and $30.1 million of state NOL carryforwards. Approximately $120.1 million of federal NOL carryforwards will expire between 2024 and 2037. Pursuant to the Tax Cuts and Jobs Act of 2017, NOLs generated after 2017 of approximately $32.0 million do not expire. The expiration of state NOL carryforwards will vary by jurisdiction. As of December 31, 2019, the Company had tax losses in the Commonwealth of Australia of approximately AU$49.1 million which can carry forward indefinitely. Federal or state NOLs cannot be used to offset taxable income in foreign jurisdictions. In addition, future utilization of NOL carryforwards in the U.S. may be subject to certain limitations under Section 382 of the Internal Revenue Code.

The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. For the years ended December 31, 2019, and 2018, the valuation allowance increased by $3.4 million and $2.2 million, respectively, primarily due to current year operating losses.

During 2018 and 2019, the Company believes it experienced an ownership change as defined in Section 382 of the Internal Revenue Code which will limit the ability to utilize the Company’s net operating losses (NOLs). The Company may have experienced additional ownership changes in earlier years further limiting the NOL carry-forwards that may be utilized. The Company has not yet completed a formal Section 382 analysis. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

The accounting guidance related to uncertain tax positions prescribes a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company had no material uncertain tax positions as of December 31, 2019 or 2018.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2019 and 2018, the Company recorded no accrued interest or penalties related to uncertain tax positions.

The tax years ended December 31, 2016 through December 31, 2019 remain open to examination by the Internal Revenue Service and for the various states where the Company is subject to taxation. Additionally, the returns of the Company’s Australian and Irish subsidiary are subject to examination by tax authorities of those jurisdictions for the tax years ended and subsequent to June 30, 2014 and December 31, 2014, respectively.

Income Taxes, Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Effective income tax rate reconciliation [Abstract]
Statutory federal income tax benefit	$ 3,802	$ 3,578
State tax benefit, net of federal taxes	46	45
Foreign tax	1	(2)
Foreign deferred exchange rate adjustments	(59)	(1,112)
Nondeductible/nontaxable items	(272)	(259)
Other	(113)	(72)
Valuation allowance increase	(3,413)	(2,184)
Total income tax expense	$ (8)	$ (6)

Stock-Based Compensation, Stock Options and Restricted Stock Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 1,512	$ 2,087
Minimum [Member]
Additional Disclosures [Abstract]
Award vesting period	1 year
Maximum [Member]
Additional Disclosures [Abstract]
Award vesting period	4 years
Selling, General and Administrative [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 1,387	1,958
Research and Development [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 125	$ 129
Stock Options [Member]
Stock Options Activity [Roll Forward]
Outstanding, beginning balance (in shares)	140,546	2,562
Granted (in shares)	281,834	163,997
Exercised (in shares)	0	0
Forfeited/expired (in shares)	(16,650)	(26,013)
Outstanding, ending balance (in shares)	405,730	140,546
Vested at the end of the year (in shares)	72,377	16,206
Weighted Average Exercise Price [Abstract]
Outstanding, beginning balance (in dollars per share)	$ 61.25	$ 1,049.93
Granted (in dollars per share)	2.38	45.76
Exercised (in dollars per share)	0	0
Forfeited/expired (in dollars per share)	31.77	61.01
Outstanding, ending balance (in dollars per share)	21.56	61.25
Vested at the end of the year (in dollars per share)	$ 74.21	$ 169.07
Weighted Average Remaining Contractual Term [Abstract]
Options outstanding, weighted average remaining contractual life	9 years 1 month 17 days
Options vested, weighted average remaining contractual life	8 years 2 months 5 days
Aggregate Intrinsic Value [Abstract]
Fair value of options, vested	$ 2,400	$ 900
Weighted Average Assumptions used in Black-Scholes Option Pricing Model [Abstract]
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.85%	2.49%
Expected volatility	121.67%	120.54%
Expected life	6 years 2 months 19 days	6 years 2 months 23 days
Additional Disclosures [Abstract]
Weighted-average fair value of options granted (in dollars per share)	$ 2.07	$ 41.04
Total unrecognized compensation costs related to non-vested stock option awards	$ 2,900
Unrecognized compensation costs related to non-vested stock option awards, recognition period	3 years 2 months 12 days
Restricted Stock Units (RSU) [Member]
Restricted Stock Awards [Roll Forward]
Nonvested, beginning balance (in shares)	3	15
Granted (in shares)	0	0
Vested (in shares)	(3)	(12)
Forfeited (in shares)	0	0
Nonvested, ending balance (in shares)	0	3
Weighted Average Grant Price [Abstract]
Nonvested, beginning balance (in dollars per share)	$ 7,297.22	$ 7,297.22
Granted (in dollars per share)	0	0
Vested (in dollars per share)	7,297.22	7,297.22
Forfeited (in dollars per share)	0	0
Nonvested, ending balance (in dollars per share)	$ 0	$ 7,297.22

Operating Leases (Details) $ in Thousands	12 Months Ended
Operating Leases (Details) $ in Thousands	Dec. 31, 2019 USD ($) $ / ft²	Dec. 31, 2018 USD ($)
Operating Leases [Abstract]
Annual base rent (per square foot) \| $ / ft²	9.00
Annual increase per square foot (in dollars per square foot) \| $ / ft²	0.25
Cost Components of Operating Leases [Abstract]
Operating lease cost	$ 213
Variable lease cost	102
Total	315
Maturities of Lease Liability [Abstract]
2020	213
2021	219
2022	55
Total lease payments	487
Less: Interest	(40)
Present value of lease liability	$ 447
Remaining lease term	2 years 3 months
Discount rate	7.50%
Operating cash outflows from operating lease	$ 206
Rent expense		$ 293
Future Minimum Lease Payments [Abstract]
2019		217
2020		220
2021		219
2022		55
2023		$ 0

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2019	Feb. 28, 2020	Jun. 30, 2019
Cover [Abstract]
Entity Registrant Name	CHF Solutions, Inc.
Entity Central Index Key	0001506492
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 8.3
Entity Common Stock, Shares Outstanding		20,806,978
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Address, State or Province	MN

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	$ 3,008	$ 2,314
Accumulated Depreciation	(2,017)	(1,778)
Property, Plant and Equipment, Net	991	536
Production Equipment [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	1,113	991
Loaners and Demo Equipment [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	801	309
Computer Software and Equipment [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	579	499
Office Furniture & Fixtures [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	291	291
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	$ 224	$ 224

Nature of Business and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Nature of Business and Significant Accounting Policies [Abstract]

Going Concern

The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2019 and 2018, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2019, the Company had an accumulated deficit of $217.5 million and it expects to incur losses for the immediate future. To date, the Company has been funded by debt and equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through the next twelve months.

The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability.

During 2018, 2019 and through January 28, 2020, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $26.0 million after deducting the underwriting discounts and commissions and other costs associated with the offerings (see Note 5 – Shareholders' Equity and Note 12-Subsequent Events). The Company will require additional funding to grow its Aquadex Business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions. Should warrant exercises not materialize or future capital raising be unsuccessful, the Company may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

Basis of Presentation

The accompanying consolidated financial statements include the accounts of CHF Solutions, Inc. and its wholly-owned subsidiaries, CHF Solutions, LLC, Sunshine Heart Company Pty Limited, and Sunshine Heart Ireland Limited. All intercompany accounts and transactions between consolidated entities have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and term deposits with original maturities of three months or less. The carrying value of these instruments approximate fair value. The balances, at times, may exceed federally insured limits. The Company has not experienced any losses on its cash and cash equivalents.

Accounts Receivable

Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and managements’ evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of December 31, 2019 or December 31, 2018. As of December 31, 2019, two customers represented 13% and 12% of the accounts receivable balance. As of December 31, 2018, three customers represented 18%, 13% and 13% of the accounts receivable balance.

Inventories

Inventories are recorded as the lower of cost or net realizable value using the first-in, first-out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. Inventories consisted of the following as of December 31:


	2019		2018
Finished Goods	$	750	$	517
Work in Process		79		34
Raw Materials		968		1,107
Total	$	1,797	$	1,658

Other Current Assets

Other current assets represent prepayments and deposits made by the Company.

Property, Plant and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed based upon the estimated useful lives of the respective assets. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Repairs and maintenance costs are expensed as incurred. The cost and accumulated depreciation of property, plant and equipment retired, or otherwise disposed of are removed from the related accounts, and any residual values are charged to expense. Depreciation expense has been calculated using the following estimated useful lives:

Production Equipment		3-7 years
Office Furniture and Fixtures		3-5 years
Computer Software and Equipment		3-4 years
Loaners and Demo Equipment		3-7 years
Leasehold Improvements		3-5 years

Depreciation expense was $239,000 and $232,000 for the years ended December 31, 2019, and 2018, respectively.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset, or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group, further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the fair value of the asset or asset group is exceeded by its carrying amount. The Company generally measures fair value by considering sale prices for similar assets or asset groups, or by discounting estimated

future cash flows from such assets or asset groups using an appropriate discount rate. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets or asset groups, and accordingly, actual results could vary significantly from such estimates. The Company periodically reviews its property and equipment for potential impairment and determines if the fair value of property and equipment equals or exceeds its carrying value. There have been no impairment losses recognized for the years ended December 31, 2019 or 2018.

Contingent Consideration

Contingent consideration

In connection with the Company’s purchase of the Aquadex Business in August 2016, the Company had an obligation to pay additional consideration that was contingent upon the occurrence of certain future events (see Note 9 - Commitments and Contingencies). Contingent consideration was recognized at the acquisition date at $126,000, the estimated fair value of the contingent milestone payments. The fair value of the contingent consideration was remeasured to its estimated fair value at the end of each reporting period, with changes recorded to earnings. During 2019, this contingency had expired, therefore its fair value was $0.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers, which the Company adopted effective January 1, 2018. Accordingly, the Company recognizes revenue when its customers obtain control of its products or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. See Note 2 – Revenue Recognition, for additional disclosures. For the years ended December 31, 2019, and 2018, one customer represented 10% of net sales.

Foreign Currency Translation

Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Assets and liabilities of foreign operations are translated at period-end exchange rates with the impacts of foreign currency translation recognized to cumulative translation adjustment, a component of accumulated other comprehensive income. Foreign currency transactions gains and losses are included in other expense, net in the consolidated statements of operations and other comprehensive loss.

Stock-Based Compensation

The Company recognizes all share-based payments to employees and directors, including grants of stock options, warrants and common stock awards in the consolidated statement of operations and comprehensive loss as an operating expense based on their fair values as established at the grant date. Equity instruments issued to non-employees include common stock awards or warrants to purchase shares of our common stock. These common stock awards or warrants are either fully-vested and exercisable at the date of grant or vest over a certain period during which services are provided. The Company expenses the fair market value of fully vested awards at the time of grant, and of unvested awards over the period in which the related services are received. In accordance with Accounting Standards Update 2018-07, unvested awards are no longer remeasured to fair value until vesting and rather the fair value is established at the grant date consistent with the treatment of employee director awards.

The Company computes the estimated fair values of stock options and warrants using the Black-Scholes option pricing model and market-based warrants using a Monte Carlo valuation model. Market price at the date of grant is used to calculate the fair value of restricted stock units and common stock awards.

Stock-based compensation expense is based on awards ultimately expected to vest and is reduced for estimated forfeitures except for market-based warrants which are expensed based on the grant date fair value regardless of whether the award vests. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

See Note 6- Stock-Based Compensation, for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Income Taxes

Deferred income taxes are provided on a liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

Loss per Share

Loss per share

Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. The net loss allocable to common stockholders for the year ended December 31, 2019, reflects a $4.5 million increase for the net deemed dividend to preferred stockholders provided in connection with the close of the public offering of Series G Convertible Preferred Stock on March 12, 2019 (see Note 5 – Shareholders' Equity), representing the intrinsic value of the shares at the time of issuance.

Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans.


	December 31,
	2019		2018
Stock options		405,730		140,546
Restricted stock units (RSU)		—		3
Warrants to purchase common stock		6,948,466		599,293
Series F convertible preferred stock		538,210		18,190
Total		7,892,406		758,032

The following table reconciles reported net loss with reported net loss per share for the years ended December 31:


(in thousands, except per share amounts)	2019			2018
Net loss	$	(18,114	)	$	(17,032	)
Deemed dividend to preferred shareholders (see Note 6)		(4,509	)		—
Net loss after deemed dividend		(22,623	)		(17,032	)
Weighted average shares outstanding		2,433			404
Basic and diluted loss per share	$	(9.30	)	$	(42.14	)

Research and Development

Research and development costs include activities related to research, development, design, and testing improvements of the Aquadex System and potential related products. Research and development costs also include expenses related to clinical research that the Company may sponsor or conduct to enhance understanding of the product and its use. Research and development expenses are expensed as incurred.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued updated guidance to improve financial reporting about leasing transactions. This guidance required organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The original guidance required application on a modified retrospective basis with the earliest period presented. In August 2018, the FASB issued new guidance which included an option to not restate comparative periods in transition. The Company adopted this new standard on January 1, 2019 with no retrospective adjustments to prior comparative periods. The adoption of this standard on January 1, 2019 resulted in an increase of approximately $0.6 million in the Company’s other long-term assets and in short and long-term liabilities recorded on its consolidated balance sheet. In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification. See Note 9 –Operating Leases for additional qualitative and quantitative disclosures

In August 2018, the FASB issued updated guidance to improve and simplify the disclosure requirements on fair value measurements for level 3 assets and liabilities valued at fair value. The Company early-adopted the guidance effective in its second quarter of 2019 and the effect on the consolidated financial statements was not material.

The Company evaluates events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,969,465	39,969,465
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	4,674,068	513,445
Common stock, shares outstanding (in shares)	4,674,068	513,445
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	535	535
Preferred stock, shares issued (in shares)	535	535
Preferred stock, shares outstanding (in shares)	535	535

Nature of Business and Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Nature of Business and Significant Accounting Policies [Abstract]

Nature of Business and Significant Accounting Policies

Note 1—Nature of Business and Significant Accounting Policies

Nature of Business

CHF Solutions, Inc. (the “Company”) is a medical device company focused on developing, manufacturing and commercializing the Aquadex FlexFlow® and Aquadex SmartFlow™ systems (herein referred to as the “Aquadex System”) for aquapheresis therapy. The Aquadex SmartFlow™ system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20kg or more whose fluid overload is unresponsive to medical management, including diuretics. CHF Solutions, Inc. is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia, Ireland and Delaware. The Company has been listed on Nasdaq since February 2012.

Previously, the Company was focused on developing the C-Pulse® Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. In August 2016, the Company acquired the business associated with the Aquadex System (herein referred to as the “Aquadex Business”) from a subsidiary of Baxter International, Inc. (“Baxter”), and refocused its strategy to fully devote its resources to the Aquadex Business.

Going Concern

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories


	2019		2018
Finished Goods	$	750	$	517
Work in Process		79		34
Raw Materials		968		1,107
Total	$	1,797	$	1,658

Other Current Assets

Other current assets represent prepayments and deposits made by the Company.

Property, Plant and Equipment

Production Equipment		3-7 years
Office Furniture and Fixtures		3-5 years
Computer Software and Equipment		3-4 years
Loaners and Demo Equipment		3-7 years
Leasehold Improvements		3-5 years

Depreciation expense was $239,000 and $232,000 for the years ended December 31, 2019, and 2018, respectively.

Contingent consideration

Revenue Recognition

Foreign Currency Translation

Stock-Based Compensation

See Note 6- Stock-Based Compensation, for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Income Taxes

Loss per share


	December 31,
	2019		2018
Stock options		405,730		140,546
Restricted stock units (RSU)		—		3
Warrants to purchase common stock		6,948,466		599,293
Series F convertible preferred stock		538,210		18,190
Total		7,892,406		758,032

The following table reconciles reported net loss with reported net loss per share for the years ended December 31:


(in thousands, except per share amounts)	2019			2018
Net loss	$	(18,114	)	$	(17,032	)
Deemed dividend to preferred shareholders (see Note 6)		(4,509	)		—
Net loss after deemed dividend		(22,623	)		(17,032	)
Weighted average shares outstanding		2,433			404
Basic and diluted loss per share	$	(9.30	)	$	(42.14	)

Research and Development

Recent Accounting Pronouncements

The Company evaluates events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Income Taxes, Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Current [Abstract]
United States and state	$ 0	$ 0
Foreign, net	(8)	(6)
Deferred [Abstract]
United States and state	0	0
Foreign	0	0
Total income tax expense	$ (8)	$ (6)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Taxes [Abstract]

Domestic and Foreign Loss Before Income Taxes

Domestic and foreign loss before income taxes, consists of the following for the years ended December 31:

(in thousands)	2019			2018
Domestic	$	(18,114	)	$	(17,027	)
Foreign		8			1
Loss before income taxes	$	(18,106	)	$	(17,026	)

Components of Income Tax Expense

The components of income tax expense consist of the following for the years ended December 31:

(in thousands)	2019			2018
Current:
United States and state	$	—		$	—
Foreign, net		(8	)		(6	)
Deferred:
United States and state		—			—
Foreign		—			—
Total income tax expense	$	(8	)	$	(6	)

Actual Income Tax Expense Differs from Statutory Federal Income Tax Expense

Actual income tax expense differs from statutory federal income tax expense as follows for the years ended December 31:

(in thousands)	2019			2018
Statutory federal income tax benefit	$	3,802		$	3,578
State tax benefit, net of federal taxes		46			45
Foreign tax		1			(2	)
Foreign deferred exchange rate adjustments		(59	)		(1,112	)
Nondeductible/nontaxable items		(272	)		(259	)
Other		(113	)		(72	)
Valuation allowance increase		(3,413	)		(2,184	)
Total income tax expense	$	(8	)	$	(6	)

Deferred Taxes

Deferred taxes consist of the following as of December 31:

(in thousands)	2019			2018
Deferred tax assets:
Noncurrent:
Accrued leave	$	51		$	50
Other accrued expenses		—			—
Stock based compensation		449			483
Net operating loss carryforward		44,572			41,032
Other		69			125
Intangibles		809			847
R&D credit carryforward		531			531
Total deferred tax assets		46,481			43,068
Less: valuation allowance		(46,481	)		(43,068	)
Total	$	—		$	—

Shareholder's Equity (Details) $ / shares in Units, $ in Thousands						12 Months Ended
	Nov. 06, 2019 USD ($) $ / shares shares	Oct. 25, 2019 USD ($) $ / shares shares	Mar. 12, 2019 USD ($) $ / shares shares	Jul. 03, 2018 USD ($) $ / shares shares	Nov. 27, 2017 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares	May 30, 2019 $ / shares shares	Dec. 31, 2018 shares
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 0.9942	$ 1.41
Preferred stock, shares outstanding (in shares)						0		0
Issuance of common stock, net (in shares)	1,219,076	575,830
Public offering price (in dollars per share) \| $ / shares	$ 1.12	$ 1.15
Warrants to purchase shares of common stock (in shares)	1,219,076	575,830
Gross proceeds from public stock offering \| $	$ 1,360	$ 660
Warrant expiry period	5 years	5 years
Warrants exercisable period		6 months
Expected Stock Price Volatility [Member]
Class of Stock Disclosures [Abstract]
Warrants measurement input						1.3621
July 2018 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares)				181,941
Public offering price (in dollars per share) \| $ / shares				$ 29.68
Gross proceeds from public stock offering \| $				$ 5,400
Net proceeds from public stock offering \| $				$ 4,600
Number of shares issuable on the exercise of warrants (in shares)				554,322
March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares)			455,178
Public offering price (in dollars per share) \| $ / shares			$ 5.25
Warrants [Member]
Class of Stock Disclosures [Abstract]
Number of warrants vested (in shares)						0
Warrants [Member] \| Minimum [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares						$ 0.99
Warrants [Member] \| Maximum [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares						43,848
Warrants [Member] \| Consultant [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares						$ 1.93	$ 3.18
Warrants to purchase shares of common stock (in shares)							100,000
Series F Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock \| $					$ 18,000
Net proceeds from issuance of convertible preferred stock \| $					$ 16,200
Conversion price (in dollars per share) \| $ / shares	$ 0.9942	$ 1.41	$ 5.25	$ 29.68	$ 63.00
Number of consecutive trading days considered for expiration						20 days
Number of consecutive trading days						30 days
Preferred stock, shares issued (in shares)					18,000	535		535
Number of shares issuable on conversion of preferred stock (in shares)					286,714
Preferred stock, shares outstanding (in shares)						535		535
Aggregate cash placement fee	8.00%	8.00%	8.00%	8.00%
Series F Convertible Preferred Stock [Member] \| Minimum [Member]
Class of Stock Disclosures [Abstract]
Percentage of volume weighted average price of common stock					300.00%
Trading volume for each trading day \| $					$ 200
Series F Convertible Preferred Stock [Member] \| Warrants [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)					573,310
Warrants issued to the placement agent (in shares)						0
Series F Convertible Preferred Stock [Member] \| Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares				$ 29.68	$ 63.00
Warrants to purchase shares of common stock (in shares)					16
Series F Convertible Preferred Stock [Member] \| Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares				$ 29.68	$ 63.00
Warrants to purchase shares of common stock (in shares)					16
Series G Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock \| $			$ 12,400
Net proceeds from issuance of convertible preferred stock \| $			$ 11,000
Conversion price (in dollars per share) \| $ / shares			$ 5.25
Number of consecutive trading days						30 days
Preferred stock, shares outstanding (in shares)						0
Beneficial conversion amount \| $						$ 4,500
Conversion of preferred stock into common stock (in shares)						1,910,536
Beneficial ownership limitation			4.99%
Series G Convertible Preferred Stock [Member] \| March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Number of shares issuable on conversion of preferred stock (in shares)			1,910,536
Series G Convertible Preferred Stock [Member] \| Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares			$ 5.25
Number of shares issuable on the exercise of warrants (in shares)			2,365,714
Series G Convertible Preferred Stock [Member] \| Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares			$ 5.25
Number of shares issuable on the exercise of warrants (in shares)			2,365,714

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 11—Related Party Transactions In January 2019, we entered into a consulting agreement with Steven Brandt, one of our non-employee directors, pursuant to which Mr. Brandt provided services, on an interim basis, until May 31, 2019, to support our commercial strategy under the direction of our Chief Executive Officer. Mr. Brandt was paid a fee of $19,000 per month, for a total of $76,000 for his services. Mr. Brandt also received $2,453 for reimbursement of expenses.

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2019

Operating Leases [Abstract]

Cost Components of Operating Leases

The cost components of the Company’s operating lease were as follows for the year ended December 31:

(in thousands)
Operating lease cost	$	213
Variable lease cost		102
Total	$	315

Maturities of Lease Liability

Maturities of our lease liability for the Company’s operating lease are as follows as of December 31, 2019:

(in thousands)
2020	$	213
2021		219
2022		55
Total lease payments		487
Less: Interest		(40	)
Present value of lease liability	$	447

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 10—Commitments and Contingencies Employee Retirement Plan The Company has a 401(k)-profit sharing plan that provides retirement benefit to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service limitations, with the Company matching a portion of the employee’s contributions at the discretion of the Company. Matching contributions totaled $227,000 and $197,000 for the years ended December 31, 2019 and 2018, respectively. Contingent Consideration In connection with the Company’s purchase of the Aquadex Business in August 2016, the Company had an obligation to pay additional consideration that was contingent upon the occurrence of certain future events. Contingent consideration was recognized at the acquisition date at $126,000, the estimated fair value of the contingent milestone payments. The fair value of the contingent consideration was remeasured to its estimated fair value at the end of each reporting period, with changes recorded to earnings. During 2019, this contingency had expired, therefore its fair value was $0.

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment were as follows:

(in thousands)	December 31,2019			December 31,2018
Production Equipment	$	1,113		$	991
Loaners and Demo Equipment		801			309
Computer Software and Equipment		579			499
Office Furniture & Fixtures		291			291
Leasehold Improvements		224			224
Total		3,008			2,314
Accumulated Depreciation		(2,017	)		(1,778	)
	$	991		$	536

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 5,511	$ 4,998
Costs and Expenses:
Cost of goods sold	2,660	3,670
Selling, general and administrative	16,285	15,311
Research and development	4,672	3,053
Total costs and expenses	23,617	22,034
Loss from operations	(18,106)	(17,036)
Other income, net	0	10
Loss before income taxes	(18,106)	(17,026)
Income tax expense	(8)	(6)
Net loss	$ (18,114)	$ (17,032)
Basic and diluted loss per share (in dollars per share)	$ (9.30)	$ (42.14)
Weighted average shares outstanding - basic and diluted (in shares)	2,433	404
Other comprehensive loss:
Foreign currency translation adjustment	$ (9)	$ (4)
Total comprehensive loss	$ (18,123)	$ (17,036)

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 13—Subsequent Event On January 28, 2020, the Company closed on an underwritten public offering of 6,046,367 shares of common stock, 11,517,269 shares of Series H Preferred Stock and warrants to purchase 17,563,636 shares of Common Stock, which includes the full exercise of the underwriter’s over-allotment option, for gross proceeds of $9.7 million. Net proceeds totaled approximately $8.6 million after deducting the underwriting discounts and commissions and other costs associated with the offering.

Nature of Business and Significant Accounting Policies, Property, Plant and Equipment, Contingent Consideration and Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Aug. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 239	$ 232
Impairment losses recognized	$ 0	$ 0
Production Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Production Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	7 years
Office Furniture & Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Office Furniture & Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years
Computer Software and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Computer Software and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	4 years
Loaners and Demo Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Loaners and Demo Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	7 years
Leasehold Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years
Aquadex Product Line [Member]
Contingent Consideration [Abstract]
Contingent consideration	$ 0		$ 126
Fair value of contingent consideration	$ 0		$ 126
ASC 606 [Member] \| Customer One [Member] \| Net Sales [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage	10.00%	10.00%

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Note 3—Property, Plant and Equipment

Property, plant and equipment were as follows:

(in thousands)	December 31,2019			December 31,2018
Production Equipment	$	1,113		$	991
Loaners and Demo Equipment		801			309
Computer Software and Equipment		579			499
Office Furniture & Fixtures		291			291
Leasehold Improvements		224			224
Total		3,008			2,314
Accumulated Depreciation		(2,017	)		(1,778	)
	$	991		$	536

Shareholder's Equity	12 Months Ended
Shareholder's Equity	Dec. 31, 2019
Shareholder's Equity [Abstract]
Shareholder's Equity	Note 5—Shareholders’ Equity Series F Convertible Preferred Stock: On November 27, 2017, the Company closed on an underwritten public offering Series F Convertible Preferred Stock and warrants to purchase shares of common stock for gross proceeds of $18.0 million. Net proceeds totaled approximately $16.2 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The offering was comprised of Series F convertible preferred stock, convertible into shares of the Company’s common stock at an initial conversion price of $63.00 per share. Each share of Series F preferred stock was accompanied by a Series 1 warrant, which was to expire on the first anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $63.00 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $63.00 per share. The Series F preferred stock has full ratchet price based anti-dilution protection, subject to customary carve outs, in the event of a down-round financing at a price per share below the conversion price of the Series F preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company’s common stock exceeds 300% of the then-effective conversion price of the Series F preferred stock and the daily dollar trading volume for each trading day during such period exceeds $200,000). The exercise price of the warrants is fixed and does not contain any variable pricing features, nor any price based anti-dilutive features, apart from customary adjustments for stock splits, combinations, reclassifications, stock dividends or fundamental transactions. A total of 18,000 shares of Series F Convertible Preferred Stock initially convertible into 286,714 shares of common stock and warrants to purchase 573,310 shares of common stock were issued in the offering. As noted below, effective July 3, 2018, the conversion price of the Series F convertible preferred stock was reduced from $63.00 to $29.68, the per share price in the July 2018 Offering described below. Effective March 12, 2019, the conversion price of the Series F convertible preferred stock was reduced from $29.68 to $5.25, the per share price to the public of the Series G convertible preferred stock which closed in an underwritten public offering on March 12, 2019. Effective October 25, 2019, the conversion price of the Series F convertible preferred stock was reduced from $5.25 to $1.41, and on November 6, 2019 from $1.41 to $0.9942, the per share price to the public in the October and November 2019 transactions, respectively, described below. As of December 31, 2019, and 2018, 535 shares of the Series F convertible preferred stock remained outstanding. July 2018 Offering: On July 3, 2018, the Company closed on an underwritten public offering of 181,941 shares of its common stock at a public offering price of $29.68 per share, for gross proceeds of $5.4 million, including the full exercise of the underwriters’ over-allotment option to purchase additional shares of the Company’s common stock (the “July 2018 Offering”). Net proceeds totaled approximately $4.6 million after deducting underwriting discounts and commissions and offering expenses. In connection with the July 2018 Offering, and to induce certain institutional investors who hold warrants issued by the Company in November 2017 (“November 2017 Warrants”) to participate in the July 2018 Offering, the Company entered into letter agreements with such institutional investors. Pursuant to the terms of these agreements, the Company agreed, effective July 3, 2018, to reduce the per share exercise price of the November 2017 Warrants held by such institutional investors to $29.68 and to extend the expiration date of the warrants that were to expire on November 27, 2018 to November 27, 2019. The number of common shares underlying the warrants that were repriced did not change. The repriced warrants are exercisable for 554,322 shares of common stock in the aggregate, of which, following such amendment, half expire on November 27, 2019 and half expire on November 27, 2024. The repricing of the warrants was accounted as an equity financing cost, with no impact to net proceeds from the offering. Series G Convertible Preferred Stock and March 2019 Offering: On March 12, 2019, the Company closed on an underwritten public offering of common stock, Series G convertible preferred stock and warrants to purchase shares of common stock for gross proceeds of $12.4 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants (“March 2019 Offering”). Net proceeds totaled approximately $11.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The Series G convertible preferred stock included a beneficial conversion amount of $4.5 million, representing the intrinsic value of the shares at the time of issuance. This amount is reflected as an increase to the loss per share allocable to common stockholders in the years ended December 31, 2019. The March 2019 Offering was comprised of 455,178 shares of common stock priced at $5.25 per share and 1,910,536 shares of Series G convertible preferred stock, convertible into common stock at $5.25 per share. Each share of Series G convertible preferred stock and each share of common stock was accompanied by a Series 1 warrant and a Series 2 warrant. The Series 1 warrants are exercisable into 2,365,714 shares of common stock and the Series 2 warrants are exercisable into 2,365,714 shares of common stock. Series 1 warrants expire on the fifth anniversary of the date of issuance and are exercisable at $5.25 to purchase one share of common stock. Series 2 warrants expire on the earlier of: (i) the eighteen-month anniversary of the date of issuance and (ii) the 30th trading day following the public announcement of the receipt from the U.S. Food and Drug Administration of clearance or approval of a modification to the product label for the Aquadex System to include pediatric patients. Series 2 warrants are exercisable at $5.25 per share of common stock. The conversion price of the Series G convertible preferred stock as well as the exercise price of the warrants are fixed and do not contain any variable pricing features, nor any price based anti-dilutive features apart from customary adjustments for splits and reverse splits of common stock. The Series G convertible preferred stock included a beneficial ownership limitation of 4.99% but had no dividend preference (except to extent dividends are also paid on the common stock), liquidation preference or other preferences over common stock. The securities comprising the units were immediately separable and were issued separately. As of December 31, 2019, all 1,910,536 shares of the Series G convertible preferred stock had been converted into common stock and none remained outstanding. October and November 2019 Offerings: On October 25, 2019, the Company closed on a registered direct offering of 575,830 shares of common stock at a price of $1.15 per share, for gross proceeds of approximately $660,000, prior to deducting commissions and expenses related to the transaction. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 575,830 shares of its common stock at an exercise price of $1.41 per share, which will be exercisable six months from the date of issuance, and will expire five years from the initial exercise date. On November 6, 2019, the Company closed on a registered direct offering of 1,219,076 shares of common stock, or common equivalents, at a price of $1.12 per share, for gross proceeds of approximately $1.36 million prior to deduction of commissions and offering expenses related to the transaction. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 1,219,076 shares of our common stock at an exercise price of $0.9942 per share, which were exercisable upon the date of issuance, and will expire five years from the initial exercise date. The unregistered warrants issued in each offering were subsequently registered pursuant to a registration statement on Form S-1 that was declared effective by the SEC on December 30, 2019. Placement Agent Fees: In connection with the issuance of the Series F convertible preferred stock, the July 2018 Offering, the March 2019 Offering, and the October and November 2019 Offerings the Company paid the placement agent an aggregate cash placement fee equal to 8% of the aggregate gross proceeds raised in the offering and issued no warrants to the placement agent. Market-Based Warrants: On May 30, 2019, the Company granted a market-based warrant to a consultant in exchange for investor relations services. The warrant represents the right to acquire up to 100,000 shares of the Company’s common stock at an exercise price of $3.18 per share, the closing stock price of the Company’s common shares on May 30, 2019. The warrant is subject to a vesting schedule based on the Company achieving certain market stock prices within a specified period of time. The warrant expires on May 30, 2024. The warrant was valued at $1.93 per share using the Monte Carlo valuation methodology and is being expensed over the term of the consulting engagement which is twelve months. Significant inputs used for the Monte Carlo valuation were the expected stock price volatility of 136.21%, and management’s expectations regarding the timing of regulatory clearance for an expanded label in pediatrics. None of these warrants had vested as of December 31, 2019.

Subsequent Events (Details) - USD ($) $ in Thousands	Jan. 28, 2020	Nov. 06, 2019	Oct. 25, 2019
Subsequent Events [Abstract]
Issuance of common stock, net (in shares)		1,219,076	575,830
Warrants to purchase shares of common stock (in shares)		1,219,076	575,830
Gross proceeds from public stock offering		$ 1,360	$ 660
Subsequent Event [Member]
Subsequent Events [Abstract]
Issuance of common stock, net (in shares)	6,046,367
Warrants to purchase shares of common stock (in shares)	17,563,636
Gross proceeds from public stock offering	$ 9,700
Net proceeds from public stock offering	$ 8,600
Series H Preferred Stock [Member] \| Subsequent Event [Member]
Subsequent Events [Abstract]
Issuance of common stock, net (in shares)	11,517,269

Nature of Business and Significant Accounting Policies, Loss Per Share and Recent Accounting Pronouncements (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	7,892,406	758,032
Reported net loss with reported net loss per share [Abstract]
Net loss	$ (18,114)	$ (17,032)
Deemed dividend to preferred shareholders (see Note 6)	(4,509)	0
Net loss after deemed dividend	$ (22,623)	$ (17,032)
Weighted average shares outstanding (in shares)	2,433,000	404,000
Basic and diluted loss per share (in dollars per share)	$ (9.30)	$ (42.14)
Recent Accounting Pronouncements [Abstract]
Operating lease right-of-use asset, net	$ 442	$ 0
Operating lease liability	$ 447
Stock Options [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	405,730	140,546
Restricted Stock Units (RSU) [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	0	3
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	6,948,466	599,293
Series F Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	538,210	18,190
ASU 2016-02 [Member] \| Adjustments Due to Adoption of ASU 2016-02 [Member]
Recent Accounting Pronouncements [Abstract]
Operating lease right-of-use asset, net	$ 600
Operating lease liability	$ 600

Nature of Business and Significant Accounting Policies, Going Concern, Accounts Receivable and Inventories (Details) - USD ($) $ in Thousands	12 Months Ended		25 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 28, 2020
Going Concern [Abstract]
Accumulated deficit	$ (217,502)	$ (199,388)
Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date	30 days
Allowance for doubtful accounts	$ 0	0
Inventories [Abstract]
Finished Goods	750	517
Work in Process	79	34
Raw Materials	968	1,107
Total	$ 1,797	$ 1,658
Subsequent Event [Member]
Going Concern [Abstract]
Net proceeds from issuance of convertible preferred stock			$ 26,000
Accounts Receivable [Member] \| Customer One [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage	13.00%	18.00%
Accounts Receivable [Member] \| Customer Two [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage	12.00%	13.00%
Accounts Receivable [Member] \| Customer Three [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage		13.00%

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Activities:
Net loss	$ (18,114)	$ (17,032)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	239	232
Stock-based compensation expense	1,512	2,087
Changes in operating assets and liabilities:
Accounts receivable	(13)	(241)
Inventories	(343)	(70)
Other current assets	42	(67)
Other assets and liabilities	18	(14)
Accounts payable and accrued expenses	292	545
Net cash used in operations	(16,367)	(14,560)
Investing activities:
Purchase of property and equipment	(490)	(198)
Net cash used in investing activities	(490)	(198)
Financing activities:
Net proceeds from public stock offerings, net	12,665	4,647
Net cash provided by financing activities	12,665	4,647
Effect of exchange rate changes on cash	(9)	(4)
Net decrease in cash and cash equivalents	(4,201)	(10,115)
Cash and cash equivalents - beginning of year	5,480	15,595
Cash and cash equivalents - end of year	1,279	5,480
Supplemental schedule of non-cash activities
Financing fees incurred for subsequent equity financing included in other assets and accounts payable	111	78
Inventory transferred to property, plant and equipment	204	0
Supplemental cash flow information
Cash paid for income taxes	$ 4	$ 2

Income Taxes, Deferred Taxes and Other Information (Details) $ in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2019 AUD ($)	Dec. 31, 2018 USD ($)
Noncurrent [Abstract]
Accrued leave	$ 51		$ 50
Other accrued expenses	0		0
Stock based compensation	449		483
Net operating loss carryforward	44,572		41,032
Other	69		125
Intangibles	809		847
R&D credit carryforward	531		531
Total deferred tax assets	46,481		43,068
Less: valuation allowance	(46,481)		(43,068)
Total	0		0
Unrecognized Tax Benefits [Abstract]
Uncertain tax positions	0		0
Penalties and Interest Accrued [Abstract]
Interest and penalties accrued on uncertain tax positions	$ 0		$ 0
Earliest Tax Year [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards, expiration date	Dec. 31, 2024
Latest Tax Year [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards, expiration date	Dec. 31, 2037
Federal [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards	$ 152,100
Net operating loss (NOL) carryforwards with expiration date	120,100
Net operating loss (NOL) carryforwards with no expiration date	32,000
State [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards	$ 30,100
Australian [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards		$ 49.0

Debt (Details) - Silicon Valley Bank [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Aug. 05, 2016
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 5.0
Term Loan [Member]
Line of Credit Facility [Abstract]
Maximum borrowing capacity			$ 4.0
Maturity date	Nov. 30, 2016
Revolving Line [Member]
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 1.0
Maturity date	Mar. 31, 2020
Total borrowings outstanding	$ 0.0	$ 0.0
Revolving Line [Member] \| Floating Annual Rate [Member]
Line of Credit Facility [Abstract]
Interest rate	1.75%
Revolving Line [Member] \| Prime Rate [Member]
Line of Credit Facility [Abstract]
Interest rate	1.00%

Commitments and Contingencies - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Aug. 31, 2016
Employee Retirement Plan [Abstract]
Employer's matching contribution	$ 227	$ 197
Aquadex Product Line [Member]
Contingent Consideration [Abstract]
Fair value of contingent consideration	0		$ 126
Contingent consideration	$ 0		$ 126

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Transfers between levels [Abstract]
Level 1 to Level 2 asset transfers	$ 0	$ 0
Level 2 to Level 1 asset transfers	0	0
Level 1 to Level 2 liability transfers	0	0
Level 2 to Level 1 liability transfers	0	$ 0
Level 3 [Member]
Fair value of Level 3 warrants [Roll Forward]
Beginning balance	126
Change in fair value	(126)
Ending balance	$ 0

Debt	12 Months Ended
Debt	Dec. 31, 2019
Debt [Abstract]
Debt	Note 4—Debt On August 5, 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (the Bank). Under this agreement, the Bank agreed to provide the Company with up to $5.0 million in debt financing, consisting of a term loan in an aggregate original principal amount not to exceed $4.0 million (the “Term Loan”) and a revolving line of credit in an aggregate principal amount not to exceed $1.0 million outstanding at any time (the “Revolving Line”). Proceeds from the loans were to be used for general corporate and working capital purposes. Advances under the Term Loan were available to the Company until November 30, 2016 and were subject to the Company’s compliance with liquidity covenants. The Term Loan expired unused on November 30, 2016 and is no longer available to be drawn. Advances under the Revolving Line are available to the Company until March 31, 2020 and accrue interest at a floating annual rate equal to 1.75% or 1.0% above the prime rate, depending on liquidity factors. Outstanding borrowings, if any, are collateralized by all of the Company’s assets, excluding intellectual property which is subject to a negative pledge. There were no borrowings outstanding under this facility as of December 31, 2019 or 2018.

Income Taxes, Domestic and Foreign Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Loss before income taxes [Abstract]
Domestic	$ (18,114)	$ (17,027)
Foreign	8	1
Loss before income taxes	$ (18,106)	$ (17,026)

Revenue Recognition (Details)	12 Months Ended
Revenue Recognition (Details)	Dec. 31, 2019	Dec. 31, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]
Expected timing of satisfaction, period	1 year	1 year
Sales Revenue [Member] \| ASC 606 [Member] \| Maximum [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales	1.00%	1.00%

Stock-Based Compensation

12 Months Ended

Dec. 31, 2019

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 6—Stock-Based Compensation

Stock Options and Restricted Stock Awards

The Company has various share-based compensation plans, including the Amended and Restated 2002 Stock Plan, the Third Amended and Restated 2017 Equity Incentive Plan, the 2013 Non-Employee Directors’ Equity Incentive Plan and the New-Hire Equity Incentive Plan (collectively, the “Plans”). The Plans are designed to assist in attracting, motivating and retaining employees and directors and to recognize the importance of employees to the long-term performance and success of the Company. The Company has also granted stock options to certain non-employees outside of the Plans.

The Company recognized stock-based compensation expense related to grants of stock options, RSUs and common stock awards to employees, directors and consultants of $1.5 million, and $2.1 million during the years ended December 31, 2019 and 2018, respectively. The following table summarizes the stock-based compensation expense which was recognized in the consolidated statements of operations for the years ended December 31,

(Dollars in thousands)	2019		2018
Selling, general and administrative	$	1,387	$	1,958
Research and development		125		129
Total	$	1,512	$	2,087

The majority of the RSUs and options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to four years. Stock-based compensation expense related to these awards is recognized on a straight-line basis over the related vesting term in most cases, which generally is the service period. It is the Company’s policy to issue new shares upon the exercise of options.

Stock Options: The following is a summary of the Plans’ stock option activity during the years ended December 31:

	2019					2018
	Options Outstanding			Weighted Average Exercise Price		Options Outstanding			Weighted Average Exercise Price
Beginning Balance		140,546		$	61.25		2,562		$	1,049.93
Granted		281,834			2.38		163,997			45.76
Exercised		—			—		—			—
Forfeited/expired		(16,650	)		31.77		(26,013	)		61.01
Outstanding at December 31		405,730		$	21.56		140,546		$	61.25
Vested at December 31		72,377		$	74.21		16,206		$	169.07

For options outstanding and vested at December 31, 2019, the weighted average remaining contractual life was 9.13 years and 8.18 years, respectively. There were no option exercises in 2019 or 2018. The total fair value of options that vested in 2019 and 2018 was $2.4 million, and $0.9 million, respectively, at the fair value of the options as of the date of grant.

Valuation Assumptions: The fair value of each stock option is estimated at the grant date using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes option pricing model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price, and expected dividends.

The Company has not historically paid cash dividends to its stockholders, and currently does not anticipate paying any cash dividends in the foreseeable future. As a result, the Company has assumed a dividend yield of 0%. The risk-free interest rate is based upon the rates of U.S. Treasury bills with a term that approximates the expected life of the option. Since the Company has limited historical exercise data to reasonably estimate the expected life of its option awards, the expected life is calculated using a simplified method. Expected volatility is based on historical volatility of the Company’s stock.

The following table provides the weighted average assumptions used in the Black-Scholes option pricing model for the years ended December 31:

	2019			2018
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.85	%		2.49	%
Expected volatility		121.67	%		120.54	%
Expected life (in years)		6.22			6.23

The weighted-average fair value of stock options granted in 2019 and 2018 was $2.07 and $41.04, respectively. As of December 31, 2019, the total compensation cost related to all non-vested stock option awards not yet recognized was approximately $2.9 million and is expected to be recognized over the remaining weighted-average period of 3.2 years.

Restricted Stock Awards: The following table summarizes restricted stock award activity during 2019 and 2018:

	2019					2018
	RSUs			Weighted Average Grant Price		RSUs			Weighted Average Grant Price
Nonvested, beginning balance		3		$	7,297.22		15		$	7,297.22
Granted		—			—		—			—
Vested		(3	)	$	7,297.22		(12	)		7,297.22
Forfeited		—			—		—			—
Nonvested at December 31		—			—		3		$	7,297.22

Warrants

Warrants to purchase 6,948,466 and 599,293 shares of common stock were outstanding at December 31, 2019 and 2018, respectively. As of December 31, 2019, warrants outstanding were exercisable at prices ranging from $0.99 to $43,848 per share, and are exercisable over a period ranging from nine months to 5.5 years.

Related Party Transactions (Details) - Steven Brandt [Member]	12 Months Ended
	Dec. 31, 2019 USD ($)
Related Party Transaction [Abstract]
Monthly fee with related party	$ 19,000
Service charges from related party	76,000
Reimbursement expenses with related party	$ 2,453